MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company listed on NASDAQ (ticker: MLTX) developing Nanobody-based immunotherapies for inflammatory and immunologic diseases. The company is advancing a pipeline of Nanobody-derived medicines through clinical trials, with programmes targeting conditions including hidradenitis suppurativa, inflammatory skin diseases, and inflammatory joint diseases where significant unmet medical need remains.
The company's technical work spans translational research, clinical development, and commercialization support. This includes ongoing trials, patient and prescriber pattern analysis to inform market decisions, and market access assessments. MoonLake translates its Nanobody platform into clinical programmes designed to modulate relevant immune pathways, supported by data and analytics capabilities that feed into go-to-market strategy.
As a public company, MoonLake maintains active investor relations and corporate communications functions. The organisation operates across immunology, dermatology, and rheumatology, positioning itself within the broader biopharmaceutical sector focused on immunologic disease treatment.
